American Made Pharmaceuticals Act of 2023
Latest Action
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-655.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The American Made Pharmaceuticals Act of 2023 is a Senate bill introduced in the 118th Congress aimed at addressing issues related to pharmaceutical manufacturing in the United States. While the official summary and full text of the bill are not available, the bill's title suggests a focus on promoting or supporting the domestic production of pharmaceuticals. The latest recorded action was a committee hearing held by the Senate Committee on Banking, Housing, and Urban Affairs on July 25, 2024. The bill ultimately failed or expired without becoming law. The policy area is health, indicating the bill's relevance to public health and pharmaceutical policy.
This bill sought to enhance the domestic pharmaceutical manufacturing sector but did not advance beyond committee hearings and ultimately expired without enactment.
- The bill was introduced in the Senate during the 118th Congress and is titled the American Made Pharmaceuticals Act of 2023.
- No official summary or full text is publicly available, limiting detailed analysis of specific provisions.
- The bill underwent committee hearings in the Senate Committee on Banking, Housing, and Urban Affairs but did not progress further.
- The bill is categorized under the health policy area, indicating its focus on pharmaceutical manufacturing and related health issues.
- The bill status is recorded as failed or expired, meaning it did not become law.
["Domestic pharmaceutical manufacturers potentially targeted by the bill's provisions to promote American-made pharmaceuticals.", 'Health sector stakeholders interested in pharmaceutical supply chains and domestic production capabilities.', 'Potentially, patients and healthcare providers if the bill aimed to improve access to domestically produced medications.']
['Lack of publicly available bill text and summary limits understanding of implementation requirements and cost implications.', 'Unclear authority and oversight mechanisms due to missing detailed provisions.', 'Potential tradeoffs between promoting domestic manufacturing and impacts on pharmaceutical pricing or supply chain dynamics.']
The bill was introduced in the Senate during the 118th Congress and was referred to the Committee on Banking, Housing, and Urban Affairs. Hearings were held, but the bill did not advance beyond this stage and expired. The focus on domestic pharmaceutical production aligns with ongoing policy discussions about supply chain resilience and national health security. However, without further legislative action, the bill did not become law.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential strengthening of domestic pharmaceutical manufacturing capacity if provisions were enacted.', 'Possible shifts in pharmaceutical supply chains favoring U.S.-based production.', 'Economic impacts on international pharmaceutical trade and import reliance.']
The absence of an official summary and full bill text significantly limits the ability to conduct a thorough analysis of the bill's provisions, potential costs, and enforcement mechanisms. Transparency in legislative documentation is essential for informed public and stakeholder engagement. The bill's failure to advance beyond committee hearings further restricts insight into legislative intent and detailed policy design.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.